Celgene Settles Patent Royalty Case for $198.5 Million

February 16, 2017

Celgene will pay $198.5 million to settle a case alleging the company failed to pay royalties on patents covering the multiple myeloma drugs Revlimid and Pomalyst/Imnovid.
Source: Drug Industry Daily

Posted in Drug Industry Daily